(NASDAQ: DVAX) Dynavax Technologies's forecast annual revenue growth rate of 16.65% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Dynavax Technologies's revenue in 2024 is $236,149,000.On average, 2 Wall Street analysts forecast DVAX's revenue for 2024 to be $36,386,586,463, with the lowest DVAX revenue forecast at $36,293,653,349, and the highest DVAX revenue forecast at $36,479,519,577. On average, 2 Wall Street analysts forecast DVAX's revenue for 2025 to be $42,182,471,382, with the lowest DVAX revenue forecast at $41,102,614,774, and the highest DVAX revenue forecast at $43,262,327,989.
In 2026, DVAX is forecast to generate $49,284,655,566 in revenue, with the lowest revenue forecast at $46,855,305,429 and the highest revenue forecast at $51,714,005,704.